Skip to content

13F-HR filed by Palo Alto Investors LP

Palo Alto Investors LP filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 38 holding rows worth $886,726,077.

Accession
0001306923-24-000008
Filed
2024-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 38 entries on the cover page, a total value of $886,726,077 stated on the cover page (in dollars after the unit check, H1), rows summing to $886,726,077 with VALUE read as dollars as filed, 13F file number 028-11013. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
INSMED INC COM PAR $.01457669307Stock4,423,369$120,006,001dollars as filed
AMICUS THERAPEUTICS INC03152W109COM9,344,102$110,073,522dollars as filed
BIOMARIN PHARMACEUTICAL INC09061G101COM1,134,569$99,093,257dollars as filed
BIOGEN INC COM09062X103Stock289,958$62,523,644dollars as filed
UNITED THERAPEUTICS CORP DEL COM91307C102Stock267,759$61,509,597dollars as filed
STAAR SURGICAL CO COM PAR $0.01852312305Stock1,379,590$52,810,705dollars as filed
ACADIA PHARMACEUTICALS INC004225108COM2,414,943$44,652,296dollars as filed
PROTHENA CORP PLC SHSG72800108Stock1,663,448$41,203,607dollars as filed
IOVANCE BIOTHERAPEUTICS INC462260100COM2,112,811$31,311,859dollars as filed
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock182,766$27,314,379dollars as filed
SAREPTA THERAPEUTICS INC803607100COM201,265$26,055,767dollars as filed
REVANCE THERAPEUTICS INC761330109COM5,248,004$25,820,180dollars as filed
SAGE THERAPEUTICS INC78667J108COM1,005,776$18,848,242dollars as filed
ANAPTYSBIO INC032724106COM799,906$18,013,883dollars as filed
EHEALTH INC28238P109COM2,715,681$16,375,556dollars as filed
ALIGN TECHNOLOGY INC COM016255101Stock49,105$16,102,512dollars as filed
ALKERMES PLCG01767105SHS495,592$13,415,675dollars as filed
ACELYRIN INC00445A100COM1,715,180$11,577,465dollars as filed
NEVRO CORP64157F103COM750,371$10,835,357dollars as filed
SYNDAX PHARMACEUTICALS INC87164F105COM405,193$9,643,593dollars as filed
NOVOCURE LTDG6674U108ORD SHS561,908$8,782,622dollars as filed
CYTOKINETICS INC23282W605COM NEW111,717$7,832,479dollars as filed
KARYOPHARM THERAPEUTICS INC48576U106COM5,102,193$7,704,311dollars as filed
VERVE THERAPEUTICS INC92539P101COM575,817$7,646,850dollars as filed
GOSSAMER BIO INC COM38341P102Stock6,391,775$7,542,295dollars as filed
ELEVATION ONCOLOGY INC COM28623U101Stock1,346,666$6,908,397dollars as filed
BLUEBIRD BIO INC09609G100COM4,560,171$5,837,019dollars as filed
RELMADA THERAPEUTICS INC75955J402COMMON STOCK732,400$3,405,660dollars as filed
NUVATION BIO INC COM CL A67080N101Stock772,652$2,812,453dollars as filed
TAYSHA GENE THERAPIES INC877619106COMMON STOCK811,268$2,328,339dollars as filed
STOKE THERAPEUTICS INC86150R107COM125,861$1,699,124dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM64,700$1,625,264dollars as filed
HUMANA INC COM444859102Stock3,985$1,381,679dollars as filed
VYNE THERAPEUTICS INC92941V308COM445,434$1,367,482dollars as filed
TRAVERE THERAPEUTICS INC89422G107COM110,719$853,643dollars as filed
ALDEYRA THERAPEUTICS INC01438T106COM225,465$737,271dollars as filed
ACLARIS THERAPEUTICS INC COM00461U105Stock569,832$706,592dollars as filed
UROGEN PHARMA LTDM96088105COMMON STOCK24,500$367,500dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001306923-24-000008this filing2024-05-15acceptance time not in the bulk data set